Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)
Phase 3
Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion) is one of 5 therapeutic programs targeting Acute Pain. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Acute Pain
#DrugCompanyPhaseTrials
1Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)
AAFT Pharmaceuticals, Ltd.
Phase 3
Aleve
Alnylam PharmaceuticalsPreclinical
Ketalar
AAultman Health Foundation
Preclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Arginine Vasopressin
SStanford University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- AAFT Pharmaceuticals, Ltd.